Table 1. List of B-CLL patients involved in this study.

Patient number	% CD5/CD19	IgVH	CD38	Age (gender)
1	85	NM	P	61 (M)
2	89	ND	P	61 (M)
3	88	NM	P	54 (M)
4	77	NM	N	62 (M)
5	85	NM	N	67 (M)
6	72	M	N	59 (F)
7	72	ND	N	72 (M)
8	70	M	P	60 (M)
9	75	NM	P	94 (M)
10	90	NM	N	70 (M)
11	80	NM	P	87 (F)
12	75	M	P	76 (M)
13	87	M	N	49 (F)
14	82	ND	N	67 (F)
15	77	ND	N	60 (M)
16	72	M	N	68 (F)
17	78	ND	P	66 (F)
18	95	NM	P	87 (M)
19	89	NM	P	50 (M)
20	93	M	N	96 (F)
21	85	M	N	70 (M)
22	81	NM	N	82 (F)
23	73	ND	P	67 (F)
24	99	NM	P	69 (F)
25	91	ND	N	61 (M)
26	80	ND	P	67 (F)
27	94	NM	P	80 (M)
28	66	M	N	57 (M)
29	75	M	P	52 (M)
30	78	NM	N	56 (M)
31	89	M	N	66 (M)
32	88	NM	P	69 (M)
33	90	M	N	68 (M)
34	84	ND	N	52 (F)
35	86	M	P	61 (F)
36	85	NM	P	63 (M)

36 patients with a diagnosis of B-CLL were involved; NM: not mutated; M: mutated; ND: not detected; P: positive (> 30% on B-cells), N: negative (< 30% on B-cells); M: male, F: female.